Despite strong revenue growth in the past, Denali Therapeuti...
Despite strong revenue growth in the past, Denali Therapeutics' lower than average P/S ratio is due to investor expectations of diminishing performance. The inferior revenue forecasts for Denali compared to its industry might continue to suppress its share price.
![](https://pubimg-10000538.picsh.myqcloud.com/2022050900000233719bee4b9bc.jpg)
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment